Document:

EX-10.1

 Exhibit 10.1 

Execution Version 

AMENDED AND RESTATED CONSULTING SERVICES AGREEMENT 

This Amended and Restated Consulting Services Agreement (this “Agreement”), dated as of October 15, 2020, by and
between Ortho-Clinical Diagnostics, Inc., a New Jersey corporation (as successor to Crimson Merger Sub, Inc., the “Company”), and Carlyle Investment Management, L.L.C., a Delaware limited liability company
(“Advisor”). 
 RECITALS 

WHEREAS, Crimson Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Advisor entered into that certain
Consulting Services Agreement dated as of June 30, 2014 (the “Prior Agreement”); 
 WHEREAS, on July 1,
2014, Merger Sub merged with and into the Company with the Company as the surviving entity; 
 WHEREAS, Advisor is an investment adviser
registered (either directly or as a relying adviser) with the Securities and Exchange Commission under the Investment Advisers Act of 1940 and acts as investment adviser or sponsor to various private equity funds that invest or hold securities in
operating companies (such as the Company) and provide investment advice to these private equity funds in connection with their investment in such portfolio companies; 

WHEREAS, Advisor, by and through its officers, employees, agents, representatives and Affiliates, has expertise in, among other things,
formation, management and structuring of businesses and organizations, business strategy, analysis of industries and markets, acquisition and disposition strategy, business due diligence, business integration and other matters relating to the
structural, strategic and financial (as opposed to operational) management of businesses; 
 WHEREAS, Advisor, in connection with providing
investment advice to or for the benefit of these private equity funds, may provide consulting services to portfolio companies in exchange for compensation, all or a portion of which may be paid to the private equity funds or applied to offset
payment obligations of the private equity funds to the Advisor; 
 WHEREAS, the Company desires to avail itself of the expertise of Advisor
in the aforesaid areas, in which it acknowledges the expertise of Advisor; and 
 WHEREAS, the Company and Advisor desire to amend and
restate the Prior Agreement in its entirety as set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and the covenants and conditions herein set forth, the parties hereto agree as
follows: 
 Section 1. Appointment. 

The Company hereby appoints Advisor to render the advisory and consulting services described in Section 2 hereof on
the terms and conditions set forth in this Agreement. 

 Section 2. Services. 

(a) In connection with the transactions contemplated by that certain Stock and Asset Purchase Agreement, dated as of January 16, 2014, by
and between Crimson Bermuda Co. Ltd., a Bermuda exempted limited liability company, and Johnson & Johnson, a New Jersey corporation (together with any and all other agreements, documents, instruments and certificates entered into in
connection with the transactions contemplated thereby and the financing thereof, the “Transaction Documents”), prior to the consummation of the transactions contemplated by the Transaction Documents, Advisor provided to the
Company strategic advisory and consulting services described on Schedule I hereto (the “New Company Advisory Services”). Nothing in this Agreement shall require Advisor to engage in any activities as a broker-dealer or
investment adviser under the laws of any jurisdiction in which it performs the services. 
 (b) The Company hereby engages Advisor to provide
to the Company, by and through such of Advisor’s officers, employees, agents, representatives and Affiliates as Advisor, in its sole discretion, shall designate (the “Advisor Designees”), from time to time as requested
by the Company and mutually agreed by the Company and Advisor, advisory, consulting and other services in relation to, among other things, development and execution of business strategy, analysis of industries and markets, acquisition and
disposition strategy, business due diligence, business integration and other matters relating to the strategic and financial (as opposed to operational) management of the businesses of the Company and its Affiliates (the “Consulting
Services”). The “Consulting Services” do not include any services related to the day-to-day operation, management or supervision of the business
or facilities of the Company and its Affiliates, including, without limitation, facility or business budget analysis, health or safety matters, regulatory compliance or policy and procedure development (the “Excluded
Services”), it being understood that Advisor will not provide and shall not be deemed to have any knowledge of activities constituting the Excluded Services. Further, in providing the Consulting Services or otherwise, Advisor shall not
be deemed to be acting in concert with the Company or any of its Affiliates, including, without limitation, for purposes of the Company’s compliance with any and all consent decrees to which the Company is party or may be party in the future.
As used herein, the term “Affiliate” of any specified person or entity means any person or entity controlling, controlled by or under common control with such specified person or entity. 

(c) It is acknowledged and agreed that, from time to time, Advisor may be requested to perform services, in addition to the New Company
Advisory Services and Consulting Services for which Advisor will be entitled to additional compensation, as set forth in Section 3(c) below. 

Section 3. Fees. 

(a) In consideration of the New Company Advisory Services provided to Merger Sub by Advisor, Merger Sub, on June 30, 2014, paid to Advisor
(or a designee of Advisor) a non-refundable and irrevocable fee of $30,000,000 in cash (the “New Company Advisory Services Fee”). 

  
 2 

 (b) In consideration of the performance of the Consulting Services contemplated by
Section 2(b) hereof, the Company agrees to pay to Advisor (or a designee of Advisor), in cash, a non-refundable and irrevocable annual fee of $3,000,000 (the “Annual
Fee” and, together with the New Company Advisory Services Fee and any fees payable pursuant to Section 3(c) hereof, the “Advisory Fees”) during the term hereof. The Annual Fee shall be
payable quarterly in advance beginning on June 30, 2014 (the “Initial Payment Date”). 
 (c) In consideration of
any services, other than the New Company Advisory Services and Consulting Services, that may be provided by Advisor to the Company from time to time during the term of this Agreement, Advisor shall be entitled to receive such additional compensation
as agreed upon by the Company and Advisor. 
 (d) Any and all payments required to be made to Advisor (or its designee) hereunder shall be
made free and clear of, and without deduction for, any federal, state, local, foreign or other taxes, duties and assessments in the nature of a tax imposed by a governmental entity or tax authority (“Taxes”), other
than any Taxes imposed on Advisor’s net income or branch profits of any jurisdiction in which Advisor is organized or in which its principal office is located, or as a result of any other present or former connection between Advisor and the
jurisdiction imposing such Taxes and any Taxes imposed as a result of Advisor’s failure timely provide an IRS Form W-9 to the Company; provided, however, that, if the Company shall be
required by applicable law to deduct any such Taxes from any payment hereunder, (i) such payment shall be increased as necessary so that, after making all required deductions (including deductions applicable to additional amounts payable under
this Section 3(d)), Advisor receives payments equal to the amount it would have received had no such deductions been made, (ii) the Company shall make such deductions and (iii) the Company shall pay the full
amount deducted to the relevant governmental authority in accordance with applicable law.    Advisor has provided to the Company an IRS Form W-9 prior to or simultaneous with the execution
of this Agreement and shall provide an IRS Form W-9 for future years at such times reasonably requested by the Company. 

Section 4. Out-of-Pocket Expenses. 

In addition to the compensation payable to Advisor pursuant to Section 3 hereof, the Company shall, promptly at the
request of Advisor, reimburse Advisor for, or at Advisor’s request, pay directly on Advisor’s behalf, the Out-of-Pocket Expenses. For the purposes of this
Agreement, the term “Out-of-Pocket Expenses” shall mean all reasonable
out-of-pocket expenses incurred or accrued by or on behalf of Advisor or its Affiliates in connection with performance of the New Company Advisory Services, the
Consulting Services or any other services provided under this Agreement (or, for the avoidance of doubt, the Prior Agreement), including, without limitation, (i) fees, expenses and disbursements of any counsel, consultants, investment bankers,
accountants, financial advisors and other independent professionals and organizations, (ii) costs of any outside services or independent contractors such as financial printers, couriers, business publications or similar services and
(iii) transportation, per diem, regulatory filing, telephone calls, word processing expenses or any similar third-party expense not associated with its ordinary operations. All reimbursements for Out-of-Pocket Expenses shall be made promptly upon presentation by Advisor to the Company of the invoices in connection therewith. 

  
 3 

 Section 5. Termination. 

(a) This Agreement will continue in full force and effect until the earlier of (i) the second anniversary of an initial public offering of
equity securities of the Company, any direct subsidiary of the Company, any other entity that, directly or indirectly, owns 100% of the equity securities of the Company, one or more subsidiaries of the Company or any of their respective successors
and (ii) the date Advisor and its Affiliates collectively and beneficially own, directly or indirectly, less than ten percent (10%) of the outstanding voting securities of the Company, its successor, any parent entity of the Company or such
successor; provided that this Agreement may be terminated at any time by written notice to the Company from Advisor. For the avoidance of doubt, termination of this Agreement will not relieve any party from liability for any breach of this
Agreement at or prior to such termination. In the event of a termination of this Agreement, on the date of such termination, the Company will pay to Advisor (or its designee) all unpaid Advisory Fees due to Advisor with respect to periods ending on
the date of termination and will reimburse Advisor for all Out-of-Pocket Expenses as of such date of termination. 

(b) Sections 4 through 14 of this Agreement shall survive termination of this Agreement with respect to matters arising before or
after such termination. 
 Section 6. Disclaimer and Limitation of Liability; Opportunities. 

(a) Disclaimer; Standard of Care. Neither Advisor nor any Advisor Designee makes any representations or warranties, express or implied,
in respect of the services to be provided by Advisor or the Advisor Designees hereunder. In no event will Advisor, any Advisor Designee or any of their respective former, current or future partners, members, stockholders, Affiliates, associates,
associated investment funds, officers, directors, employees, controlling persons, agents or representatives, or any former, current or future partners, members, stockholders, Affiliates, associates, associated investment funds, officers, directors,
employees, controlling persons, agents or representatives of any of the foregoing (together with Advisor and the Advisor Designees, the “Advisor Related Parties”) be liable to the Company or any of its
Affiliates for any act, alleged act, omission or alleged omission hereunder that does not constitute a breach of this Agreement by, or gross negligence or willful misconduct of, Advisor or an Advisor Designee, as determined by a final, non-appealable determination of a court of competent jurisdiction. 
 (b) Freedom to Pursue
Opportunities. In recognition that the Advisor Related Parties currently have, and will in the future have or will consider acquiring, investments in numerous companies with respect to which one or more Advisor Related Parties may serve as an
advisor, a director or in some other capacity, and in recognition that the Advisor Related Parties have myriad duties to various investors and partners, and in anticipation that the Company and its Affiliates, on the one hand, and the Advisor
Related Parties, on the other hand, may engage in the same or similar activities or lines of business and have an interest in the same areas of corporate opportunities, and in recognition of the benefits to be derived by the Company and its
Affiliates hereunder and in recognition of the difficulties which may confront any advisor who desires and endeavors fully to satisfy such advisor’s duties in determining the full scope of such duties in any particular situation, the provisions
of this Section 6(b) are set forth to regulate, 

  
 4 

 
define and guide the conduct of certain affairs of the Company and its subsidiaries as they may involve the Advisor Related Parties. Except as Advisor may otherwise agree in writing after the
date hereof: 
 (i) Each Advisor Related Party will have the right: (A) to directly or indirectly engage in any business (including,
without limitation, any business activities or lines of business that are the same as or similar to those pursued by, or competitive with, the Company or any of its Affiliates), (B) to directly or indirectly do business with any client or customer
of the Company or any of its Affiliates, (C) to take any other action that such Advisor Related Party believes in good faith is necessary to or appropriate to fulfill its obligations as described in the first sentence of this
Section 6(b) to persons or entities other than the Company and its Affiliates, and (D) not to communicate or present potential transactions, matters or business opportunities to the Company or any of its Affiliates,
and to pursue, directly or indirectly, any such opportunity for itself or a persons or entities other than the Company and its Affiliates, and to direct any such opportunity to another person or entity. 

(ii) No Advisor Related Party will have any duty (contractual or otherwise) to communicate or present any corporate opportunities to the
Company or any of its Affiliates or to refrain from any actions specified in Section 6(b)(i), and the Company, on behalf of itself and its subsidiaries, hereby renounces and waives any right to require any Advisor Related
Party to act in a manner inconsistent with the provisions of this Section 6(b). 
 (iii) Except as provided in this
Section 6(b), no Advisor Related Party will be liable to the Company or any of its subsidiaries for breach of any duty (contractual or otherwise) by reason of any activities or omissions of the types referred to in this
Section 6(b) or of any such person’s participation therein. 
 (c) Limitation of Liability. In no event
will any Advisor Related Party be liable to the Company or any of its Affiliates for any indirect, special, incidental or consequential damages, including, without limitation, lost profits or savings, whether or not such damages are foreseeable,
relating to, in connection with or arising out of this Agreement or the performance of the services contemplated hereby, before termination of this Agreement, including, without limitation, the services to be provided by Advisor or any Advisor
Designee hereunder. In no event will any Advisor Related Party be liable for damages of any kind relating to, in connection with or arising out of this Agreement for any act or omission that does not constitute a breach of this Agreement by, or
gross negligence or willful misconduct of, Advisor or an Advisor Designee (as determined by a final non-appealable judgment of a court of competent jurisdiction) or for damages in excess of the fees received
by Advisor hereunder for the service to which such act or omission relates. 

  
 5 

 Section 7. Indemnification 

(a) The Company will indemnify, defend, exonerate and hold harmless the Advisor Related Parties from and against any and all actions, causes of
action, suits, claims, liabilities, losses, damages, costs and expenses (including, without limitation reasonable attorneys’ fees, expenses and disbursements) incurred by the Advisor Related Parties or any of them before or after the date of
this Agreement, arising out of, incurred in connection with or as a result of, or in any way relating to, (i) this Agreement, the Transaction Documents, any transaction to which the Company or any of its Affiliates is a party or any other
circumstances with respect to the Company or any of its Affiliates or the conduct of the business of the Company and its Affiliates or (ii) services provided by Advisor or any Advisor Designee to the Company or any of its Affiliates from time
to time pursuant to this Agreement (collectively, the “Indemnified Liabilities”); provided that the foregoing indemnification rights will not be available to the extent that a court of competent
jurisdiction determines by final non-appealable judgment or order that such Indemnified Liabilities arose on account of such Advisor Related Party’s gross negligence or willful misconduct; and
provided, further, that if and to the extent that the foregoing right to indemnification may be unavailable or unenforceable for any reason, the Company hereby agrees to make the maximum contribution to the payment and satisfaction of
each of the Indemnified Liabilities which is permissible under applicable law. 
 (b) The Company will reimburse any Advisor Related Party
for all reasonable costs and expenses (including reasonable attorneys’ fees and expenses and any other litigation-related expenses) as they are incurred in connection with investigating, preparing, pursuing, defending or assisting in the
defense of any action, claim, suit, investigation or proceeding for which the Advisor Related Party would be entitled to indemnification under the terms of Section 7(a), or any action or proceeding arising therefrom,
whether or not such Advisor Related Party is a party thereto. The Company agrees that it will not, without the prior written consent of Advisor, settle, compromise or consent to the entry of any judgment in any pending or threatened claim, action or
proceeding relating to the matters contemplated hereby (if any Advisor Related Party is a party thereto or has been threatened to be made a party thereto) unless such settlement, compromise or consent includes an unconditional release of the Advisor
Related Party from all liability, without future obligation or prohibition on the part of such Advisor Related Party, arising or that may arise out of such claim, action or proceeding, and does not contain an admission of guilt or liability on the
part of the Advisor Related Party. 
 (c) The rights of any Advisor Related Party to indemnification hereunder will be in addition to any
other rights any such person may have under any other agreement or instrument referenced above or any other agreement or instrument to which such Advisor Related Party is or becomes a party or is or otherwise becomes a beneficiary or under law or
regulation. The Company hereby acknowledges that each Advisor Related Party may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more persons or entities with whom or which such Advisor Related
Party may be associated (including, without limitation, any other Advisor Related Party). The Company hereby acknowledges and agrees that (i) the Company shall be the indemnitor of first resort with respect to any Indemnified Liability,
(ii) the Company shall be primarily liable for all Indemnified Liabilities and any indemnification afforded to any Advisor Related Party in respect of any Indemnified Liabilities, whether created by law, organizational or constituent documents,
contract (including this Agreement) or otherwise, (iii) any obligation of any other person or entity with whom or which any Advisor Related Party may be associated (including, without limitation, any other Advisor Related Party) to indemnify
such Advisor Related Party and/or advance expenses to such Advisor Related Party in respect of any proceeding shall be secondary to the obligations of the 

  
 6 

 
Company hereunder, (iv) the Company shall be required to indemnify each Advisor Related Party and advance expenses to each Advisor Related Party hereunder to the fullest extent provided
herein without regard to any rights such Advisor Related Party may have against any other person or entity with whom or which such Advisor Related Party may be associated (including, without limitation, any other Advisor Related Party) or insurer of
any such person or entity and (v) the Company irrevocably waives, relinquishes and releases any other person or entity with whom or which any Advisor Related Party may be associated from any claim of contribution, subrogation or any other
recovery of any kind in respect of amounts paid by the Company hereunder. In the event any other person or entity with whom or which any Advisor Related Party may be associated (including, without limitation, any other Advisor Related Party) or
their insurers advances or extinguishes any liability or loss which is the subject of any Indemnified Liability owed by the Company or payable under any insurance policy provided under this Agreement, the payor shall have a right of subrogation
against the Company or its insurer or insurers for all amounts so paid which would otherwise be payable by the Company or its insurer or insurers under this Agreement. In no event will payment of an Indemnified Liability under this Agreement by any
other person or entity with whom or which any Advisor Related Party may be associated (including, without limitation, other Advisor Related Parties) or their insurers affect the obligations of the Company hereunder or shift primary liability for any
Indemnified Liability to any other person or entity with whom or which such Advisor Related Party may be associated (including, without limitation, any other Advisor Related Party). 

Section 8. Amendments and Waivers. 

The Prior Agreement is hereby amended and restated by this Agreement, provided that for the avoidance of doubt, references to this Agreement
include (with respect to periods prior to the date hereof) the Prior Agreement. No amendment or waiver of any provision of this Agreement, or consent to any departure by either party from any such provision, shall be effective unless the same shall
be in writing and signed by the parties to this Agreement, and, in any case, such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given. The waiver by any party of any breach of
this Agreement shall not operate as or be construed to be a waiver by such party of any subsequent breach. 
 Section 9.
Assignment. 
 This Agreement and the rights of the parties hereunder may not be assigned without the prior written consent of the
parties hereto; provided, however, that Advisor may assign or transfer its duties or interests hereunder to an Affiliate of Advisor at the sole discretion of Advisor. Subject to the foregoing, the provisions of this Agreement will be
binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the next sentence, no person or party other than the parties hereto and their respective successors or permitted assigns is intended
to be a beneficiary of this Agreement. The parties acknowledge and agree that each of the Advisor Related Parties shall be third-party beneficiaries with respect to Sections 6 and 7 hereof, in each case entitled to enforce such
provisions as though each such Advisor Related Party were a party to this Agreement. 

  
 7 

 Section 10. Notices. 

Any and all notices hereunder shall, in the absence of receipted hand delivery, be deemed duly given when delivered, if the same shall be sent
by registered or certified mail, post prepaid, facsimile, email, overnight courier or hand delivery. Notices shall be addressed to the parties at the following addresses: 
  

					
		 	If to Advisor:	  	Carlyle Investment Management, L.L.C.
		 		  	520 Madison Avenue, 39th Floor
		 		  	New York, NY 10022
		 		  	Attention: Stephen H. Wise
		 		  	Facsimile: (212) 893-4901
		 		  	Email: Steve.Wise@carlyle.com
			
		 	with a copy to:	  	Latham & Watkins LLP
		 		  	555 Eleventh Street, N.W.
		 		  	Suite 1000
		 		  	Washington, D.C. 20004
		 		  	Attention: Daniel T. Lennon, Esq.
		 		  	                 David I. Brown, Esq.
		 		  	Facsimile: (202) 637-2201
		 		  	Email: Daniel.Lennon@lw.com
		 		  	            David.Brown@lw.com
			
		 	If to the Company:	  	Ortho-Clinical Diagnostics, Inc.
		 		  	1001 Route 202
		 		  	Raritan, NJ 08869
		 		  	Attention: Michael A. Schlesinger
		 		  	Facsimile: +91-22-67879333
		 		  	Email:
		 		  	Michael.Schlesinger@orthoclinicaldiagnosics.com

 Section 11. Entire Agreement. 

This Agreement shall constitute the entire agreement between the parties with respect to the subject matter hereof, and shall supersede all
previous oral and written (and all contemporaneous oral) negotiations, commitments, agreements and understandings relating hereto. 

Section 12. GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL; SPECIFIC PERFORMANCE. 

THIS AGREEMENT SHALL BE GOVERNED BY, CONSTRUED, APPLIED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO
CONTRACTS EXECUTED AND TO BE PERFORMED WHOLLY WITHIN SUCH STATE AND WITHOUT REFERENCE TO THE CHOICE-OF-LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF
A DIFFERENT JURISDICTION. EACH OF THE PARTIES HERETO ACKNOWLEDGES 

  
 8 

 
AND AGREES THAT IN THE EVENT OF ANY BREACH OF THIS AGREEMENT, THE NON-BREACHING PARTY WOULD BE IRREPARABLY HARMED AND COULD NOT BE MADE WHOLE BY MONETARY
DAMAGES, AND THAT, IN ADDITION TO ANY OTHER REMEDY TO WHICH THEY MAY BE ENTITLED AT LAW OR IN EQUITY, THE PARTIES SHALL BE ENTITLED TO SUCH EQUITABLE OR INJUNCTIVE RELIEF AS MAY BE APPROPRIATE. THE CHOICE OF FORUM SET FORTH IN THIS SECTION SHALL NOT
BE DEEMED TO PRECLUDE THE ENFORCEMENT OF ANY JUDGMENT OF A COURT DESCRIBED IN CLAUSE (1) OF THIS SECTION BELOW, OR THE TAKING OF ANY ACTION UNDER THIS AGREEMENT TO ENFORCE SUCH A JUDGMENT, IN ANY OTHER APPROPRIATE JURISDICTION. 

IN THE EVENT ANY PARTY TO THIS AGREEMENT COMMENCES ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION IN CONNECTION WITH OR RELATING TO THIS
AGREEMENT, ANY RELATED AGREEMENT OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN OR THEREIN, THE PARTIES TO THIS AGREEMENT HEREBY (1) AGREE UNDER ALL CIRCUMSTANCES ABSOLUTELY AND IRREVOCABLY TO INSTITUTE ANY LITIGATION, PROCEEDING OR OTHER
LEGAL ACTION IN THE SUPREME COURT OF THE STATE OF NEW YORK, COUNTY OF NEW YORK, OR, IF UNDER APPLICABLE LAW EXCLUSIVE JURISDICTION IS VESTED IN THE U.S. FEDERAL COURTS, THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK (AND
APPELLATE COURTS THEREOF); (2) AGREE THAT IN THE EVENT OF ANY SUCH LITIGATION, PROCEEDING OR ACTION, SUCH PARTIES WILL CONSENT AND SUBMIT TO THE PERSONAL JURISDICTION OF ANY SUCH COURT DESCRIBED IN CLAUSE (1) OF THIS SECTION AND TO SERVICE OF
PROCESS UPON THEM IN ACCORDANCE WITH THE RULES AND STATUTES GOVERNING SERVICE OF PROCESS (IT BEING UNDERSTOOD THAT NOTHING IN THIS SECTION SHALL BE DEEMED TO PREVENT ANY PARTY FROM SEEKING TO REMOVE ANY ACTION TO THE UNITED STATES DISTRICT COURT FOR
THE SOUTHERN DISTRICT OF NEW YORK); (3) AGREE TO WAIVE TO THE FULL EXTENT PERMITTED BY LAW ANY OBJECTION THAT THEY MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH LITIGATION, PROCEEDING OR ACTION IN ANY SUCH COURT OR THAT ANY SUCH LITIGATION,
PROCEEDING OR ACTION WAS BROUGHT IN ANY INCONVENIENT FORUM; (4) AGREE, AFTER CONSULTATION WITH COUNSEL, TO WAIVE ANY RIGHTS TO A JURY TRIAL TO RESOLVE ANY DISPUTES OR CLAIMS RELATING TO THIS AGREEMENT; (5) AGREE TO SERVICE OF PROCESS IN
ANY LEGAL PROCEEDING BY MAILING OF COPIES THEREOF TO SUCH PARTY AT ITS ADDRESS SET FORTH HEREIN FOR COMMUNICATIONS TO SUCH PARTY; (6) AGREE THAT ANY SERVICE MADE AS PROVIDED HEREIN SHALL BE EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT; AND
(7) AGREE THAT NOTHING HEREIN SHALL AFFECT THE RIGHTS OF ANY PARTY TO EFFECT SERVICE OF PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. 

Section 13. Counterparts. 

This Agreement may be executed in two or more counterparts, and by different parties on separate counterparts. Each set of counterparts showing
execution by all parties shall be deemed an original, and shall constitute one and the same instrument. 

  
 9 

 Section 14. Severability. If any provision or provisions of this Agreement shall
be held to be invalid or unenforceable, the validity, legality and enforceability of the remaining provisions hereof shall not any way be affected or impaired thereby. 

[Signature Page Follows] 

  
 10 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered by
their duly authorized officers or agents as of the date first referenced above as set forth below. 
  

			
	CARLYLE INVESTMENT MANAGEMENT, L.L.C.
		
	By:	 	/s/ Jeffrey Ferguson
	Name: Jeffrey Ferguson
	Title:   Authorized Person
	
	ORTHO-CLINICAL DIAGNOSTICS, INC.
		
	By:	 	/s/ Chris M. Smith
	Name: Chris M. Smith
	Title:   CEO

 Schedule I 

Strategic and advisory consulting services, including, without limitation: 

 

	 	i.	 transaction structuring services and acquisition due diligence services; 

 

	 	ii.	 consulting services with respect to the corporate, operational and organizational structure for the Company and
its subsidiaries; 

  

	 	iii.	 assisting in identifying, contacting, and recruiting new management and operational personnel;

  

	 	iv.	 assistance in establishing treasury, accounting, information technology, financial reporting, accounting, human
resources and payroll, insurance, contract management and other “day one” administrative functions and infrastructure; 

  

	 	v.	 assistance in establishing appropriate policies, procedures and processes for its business;

  

	 	vi.	 assistance negotiating the terms of and advice concerning the implementation of transition services from
Johnson & Johnson; 

  

	 	vii.	 advice and assistance concerning transition planning; 

 

	 	viii.	 advice and assistance concerning initial Company business plan and budgets; 

 

	 	ix.	 assistance implementing corporate operational and organizational structure; and 

 

	 	x.	 assistance negotiating the terms of commercial, technical, and administrative services to be provided by
affiliates of Johnson & Johnson following the transactions.EX-10.2

 Exhibit 10.2 
  

 
  

FORM OF PRINCIPAL SHAREHOLDERS AGREEMENT 

BY AND AMONG 

ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC 

AND 
 THE
CARLYLE SHAREHOLDER 
 [ ● ], 2021 

 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 SECTION I.
	 	 DEFINITIONS
	  	 	1	 
	 1.1
	 	 Drafting Conventions; No Construction Against Drafter
	  	 	1	 
	 1.2
	 	 Defined Terms
	  	 	2	 
			
	 SECTION II.
	 	 REPRESENTATIONS AND WARRANTIES
	  	 	3	 
	 2.1
	 	 Representations and Warranties of the Initial Carlyle Shareholder
	  	 	3	 
	 2.2
	 	 Representations and Warranties of the Company
	  	 	4	 
			
	 SECTION III.
	 	 REGISTRATION RIGHTS
	  	 	4	 
	 3.1
	 	 Demand and Piggyback Rights.
	  	 	4	 
	 3.2
	 	 Notices, Cutbacks and Other Matters.
	  	 	5	 
	 3.3
	 	 Facilitating Registrations and Offerings.
	  	 	8	 
	 3.4
	 	 Indemnification.
	  	 	13	 
	 3.5
	 	 Rule 144
	  	 	15	 
			
	 SECTION IV.
	 	 MISCELLANEOUS PROVISIONS
	  	 	15	 
	 4.1
	 	 Information and Access Rights
	  	 	15	 
	 4.2
	 	 Confidentiality
	  	 	18	 
	 4.3
	 	 Reliance
	  	 	18	 
	 4.4
	 	 Access to Agreement; Amendment and Waiver; Actions of the Board
	  	 	18	 
	 4.5
	 	 Notices
	  	 	18	 
	 4.6
	 	 Counterparts
	  	 	19	 
	 4.7
	 	 Remedies; Severability
	  	 	19	 
	 4.8
	 	 Entire Agreement
	  	 	20	 
	 4.9
	 	 Termination
	  	 	20	 
	 4.10
	 	 Governing Law
	  	 	20	 
	 4.11
	 	 Successors and Assigns; Beneficiaries
	  	 	20	 
	 4.12
	 	 Consent to Jurisdiction; Specific Performance; WAIVER OF JURY TRIAL
	  	 	20	 
	 4.13
	 	 Further Assurances; Company Logo
	  	 	21	 
	 4.14
	 	 Regulatory Matters
	  	 	21	 
	 4.15
	 	 Inconsistent Agreements
	  	 	21	 
	 4.16
	 	 In-Kind Distributions
	  	 	21	 
	 4.17
	 	 Recapitalization Transactions.
	  	 	21	 

 EXHIBIT 
 Exhibit
A: Form of Joinder Agreement 
  

  
 i 

 PRINCIPAL SHAREHOLDERS AGREEMENT 

This Principal Shareholders Agreement (this “Agreement”) is made as of [ ● ],
2021 by and among Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated and registered in England and Wales (the “Company”), and Carlyle Partners VI Cayman Holdings, L.P., a Cayman Islands exempted
limited partnership (the “Initial Carlyle Shareholder”), and any other shareholder who from time to time becomes party to this Agreement by execution of a joinder agreement substantially in the form of Exhibit A (a
“Joinder Agreement”). 
 RECITALS 

A. The Company is proposing to consummate an initial public offering of its share capital (the “Initial Public Offering”).

 B. The Initial Carlyle Shareholder and the Company desire to enter into this Agreement effective upon the effective date of the
registration statement relating to the Initial Public Offering (the “Effective Date”). 
 C. The Board of Directors of the
Company (the “Board of Directors”) has approved this Agreement. 
 D. The parties hereto desire to agree upon the respective
rights and obligations after the Effective Date with respect to the securities of the Company now or hereafter issued and outstanding and held by the parties to this Agreement and certain matters with respect to their investment in the Company. 

AGREEMENT 
 Now therefore,
in consideration of the foregoing, and the mutual agreements and covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

SECTION I. DEFINITIONS 
 1.1 Drafting
Conventions; No Construction Against Drafter. 
 (a) The headings in this Agreement are provided for convenience and do not affect its
meaning. The words “include,” “includes” and “including” are to be read as if they were followed by the phrase “without limitation.” Unless specified otherwise, any reference to an agreement means that
agreement as amended or supplemented, subject to any restrictions on amendment contained in such agreement. Unless specified otherwise, any reference to a statute or regulation means that statute or regulation as amended or supplemented from time to
time and any corresponding provisions of successor statutes or regulations. If any date specified in this Agreement as a date for taking action falls on a day that is not a business day, then that action may be taken on the next business day. Unless
specified otherwise, the words “party” and “parties” refer only to a party named in this Agreement or one who joins this Agreement as a party pursuant to the terms hereof. 

(b) The language used in this Agreement shall be deemed to be the language chosen by the parties to express their mutual intent. If an
ambiguity or question of intent or interpretation arises, this Agreement is to be construed as if drafted jointly by the parties and there is to be no presumption or burden of proof or rule of strict construction favoring or disfavoring any party
because of the authorship of any provision of this Agreement. 
  

  
 1 

 1.2 Defined Terms. The following capitalized terms, as used in this Agreement, shall
have the meanings set forth below. 
 “Affiliate” shall mean with respect to any specified Person, any other Person which,
directly or indirectly, controls, is controlled by or is under common control with the specified Person, including any partner, officer, director or member of the specified Person and, if the specified Person is a private equity fund, any investment
fund now or hereafter managed by, or which is controlled by or is under common control with, one or more general partners or managing members of, or shares the same management company with, the specified Person or any investment fund, managed
account vehicle, collective investment scheme or comparable investment vehicle (“Fund”) now or hereafter existing that shares the same management company or registered investment advisor with such Person or any Fund now or hereafter
existing that is controlled by, under common control with, managed or advised by the same management company or registered investment advisor that controls, is under common control with, manages or advises the Fund that controls such Person. For the
purposes of this definition, “control” (including, with its correlative meanings, the terms “controlled by” and “under common control with”), as used with respect to any Person, shall mean the possession, directly or
indirectly, of the power to direct, or cause the direction of the management and policies of such Person, whether through the ownership of securities, by contract or otherwise. 

“Articles of Association” shall mean the Company’s articles of association in effect as of the Effective Date, as
amended from time to time. 
 “Carlyle Majority Interest” shall mean, at any given time, the Carlyle Shareholders holding a
majority of the outstanding Shares held at that specified time by all Carlyle Shareholders. 
 “Carlyle Shareholders” means
(i) the Initial Carlyle Shareholder and (ii) any Permitted Transferee or Affiliate of the Initial Carlyle Shareholder (x) which is issued Ordinary Shares or becomes the beneficial owner of any Ordinary Shares or is Transferred any
Ordinary Shares by any other Person and (y) which becomes a party hereto by executing a Joinder Agreement. 

“Charter” shall mean the Company’s certificate of incorporation in effect as of the Effective Date, as amended from time
to time. 
 “Company” shall have the meaning set forth in the preamble and shall include any successor thereto. 

“Director” shall mean a member of the Board of Directors. 

“Exchange Act” shall mean the Securities Exchange Act of 1934 and the rules and regulations thereunder. 

“FINRA” shall mean the Financial Industry Regulatory Authority. 

“GAAP” means generally accepted accounting principles, as in effect in the United States of America from time to time. 

“Initial Capital Interest” means the aggregate sums which remain invested by a Shareholder in shares and yield free
convertible preferred equity certificates of the Company immediately following the IPO. 

  
 2 

 “IPO” means the underwritten registered public offering of the
Company’s Ordinary Shares pursuant to which the Ordinary Shares are being listed on Nasdaq . 
 “Nasdaq” means the
Nasdaq Stock Market. 
 “Ordinary Shares” shall mean the ordinary shares, nominal value of USD $0.00001 per share, of the
Company. 
 “Permitted Transferee” shall mean, with respect to the Carlyle Shareholder, (i) any Affiliate of the
Carlyle Shareholder, (ii) any director, officer or employee of any Affiliate of such Carlyle Shareholder, (iii) any direct or indirect member or general or limited partner of such Carlyle Shareholder that is the transferee of Shares
pursuant to a pro rata distribution of Shares by such Carlyle Shareholder to its partners or members, as applicable (or any subsequent transfer of such Shares by the transferee to another Permitted Transferee) or (iv) any other Transferee
designated as a Permitted Transferee by the Carlyle Majority Interest. 
 “Person” shall mean an individual, corporation,
partnership, limited liability company, joint venture, association, trust, unincorporated organization, government (or agency or political subdivision thereof) or any other entity or group (as defined in Section 13(d) of the Exchange Act). 

“Public Offering” shall mean a public offering and sale of Ordinary Shares for cash pursuant to an effective registration
statement under the Securities Act. 
 “SEC” shall mean the Securities and Exchange Commission. 

“Securities Act” shall mean the Securities Act of 1933 and the rules and regulations thereunder. 

“Shares” shall mean, at any time, (i) Ordinary Shares and (ii) any other equity securities now or hereafter issued
by the Company, together with any options, warrants or other rights thereon and any other shares or other equity securities issued or issuable with respect thereto (whether by way of a share dividend, share split or in exchange for or in replacement
or upon conversion of such shares or otherwise in connection with a combination of shares, recapitalization, merger, consolidation or other corporate reorganization). 

“Shareholders” means the Carlyle Shareholder and any other shareholders who from time to time become party to this Agreement
by execution of a Joinder Agreement. 
 “Transfer” means any direct or indirect transfer, donation, sale, assignment,
pledge, hypothecation, grant of a security interest in or other disposal or attempted disposal of all or any portion of a security, any interest or rights in a security, or any rights under this Agreement. 

“Transferee” means the recipient of a Transfer. 

“WKSI” means a well-known seasoned issuer, as defined in the SEC’s Rule 405. 

SECTION II. REPRESENTATIONS AND WARRANTIES 

2.1 Representations and Warranties of the Initial Carlyle Shareholder. The Initial Carlyle Shareholder hereby represents, warrants and
covenants to the Company as follows: (a) such Initial Carlyle Shareholder has full limited partnership power and authority to enter into this Agreement and perform its obligations hereunder; (b) this Agreement constitutes the valid and
binding obligation of such Initial Carlyle Shareholder enforceable against it in accordance with its terms; and (c) the execution, delivery and 

  
 3 

 
performance by such Initial Carlyle Shareholder of this Agreement: (i) does not and will not violate any laws, rules or regulations of the United States or any state or other jurisdiction
applicable to such Initial Carlyle Shareholder, or require such Initial Carlyle Shareholder to obtain any approval, consent or waiver of, or to make any filing with, any Person that has not been obtained or made; and (ii) does not constitute a
breach of or default under any material agreement to which such Initial Carlyle Shareholder is a party. 
 2.2 Representations and
Warranties of the Company. The Company hereby represents, warrants and covenants to the Shareholders as follows: (a) the Company has full corporate power and authority to enter into this Agreement and perform its obligations hereunder;
(b) this Agreement constitutes the valid and binding obligation of the Company enforceable against it in accordance with its terms; and (c) the execution, delivery and performance by the Company of this Agreement: (i) does not and
will not violate any laws, rules or regulations of the United States or any state or other jurisdiction applicable to the Company, or require the Company to obtain any approval, consent or waiver of, or to make any filing with, any Person that has
not been obtained or made; and (ii) does not and will not result in a breach of, constitute a default under, accelerate any obligation under or give rise to a right of termination of any indenture or loan or credit agreement or any other
material agreement, contract, instrument, mortgage, lien, lease, permit, authorization, order, writ, judgment, injunction, decree, determination or arbitration award to which the Company is a party or by which the property of the Company is bound or
affected, or result in the creation or imposition of any mortgage, pledge, lien, security interest or other charge or encumbrance on any of the assets or properties of the Company. 

SECTION III. REGISTRATION RIGHTS 
 3.1
Demand and Piggyback Rights. 
 (a) Right to Demand a Non-Shelf Registered Offering.
Upon the demand of any Carlyle Shareholder at any time and from time to time after (or in advance of, but subject to) the expiration or waiver of the underwriter lock-up period applicable to the Company’s
IPO, the Company will facilitate in the manner described in this Agreement a non-shelf registered offering of the Shares requested by the demanding Carlyle Shareholders to be included in such offering. A
demand by Carlyle Shareholders for a non-shelf registered offering that will result in the imposition of a lockup on the Company and the Shareholders may not be made unless the Shares requested to be sold by
the demanding Carlyle Shareholders in such offering have an aggregate market value (based on the most recent closing price of the Ordinary Shares at the time of the demand) of at least $50 million (or such lesser amount if all Shares held by
the demanding Carlyle Shareholders are requested to be sold). 
 (b) Right to Piggyback on a
Non-Shelf Registered Offering. In connection with any registered offering of Ordinary Shares covered by a non-shelf registration statement (whether pursuant to the
exercise of demand rights or at the initiative of the Company), the Carlyle Shareholders may exercise piggyback rights to have included in such offering Shares held by them. The Company will facilitate in the manner described in this Agreement any
such non-shelf registered offering. 
 (c) Right to Demand and be Included in a Shelf
Registration. Upon the demand of any Carlyle Shareholder, made at any time and from time to time when the Company is eligible to utilize Form S-3 or a successor form to sell Shares in a secondary offering
on a delayed or continuous basis in accordance with Rule 415, the Company will facilitate in the manner described in this Agreement a shelf registration of Shares held by such Carlyle Shareholder. Unless otherwise requested by any Carlyle
Shareholder, any shelf registration filed by the Company covering Shares (whether pursuant to a Carlyle Shareholder demand or at the initiative of the Company) will cover Shares held by each of the Carlyle Shareholders (regardless of whether they
demanded the filing of such shelf or not) up to an equivalent percentage of their original respective holdings as may be agreed upon by the demanding Carlyle Shareholders. If at the time of such request the Company is a WKSI, such shelf registration
would, at the request of such Carlyle Shareholders, cover an unspecified number of Shares to be sold by the Company and the Carlyle Shareholders. 

  
 4 

 (d) Demand and Piggyback Rights for Shelf Takedowns. Upon the demand of one or more
Carlyle Shareholders made at any time and from time to time, the Company will facilitate in the manner described in this Agreement a “takedown” of Shares off of an effective shelf registration statement. In connection with any underwritten
shelf takedown (whether pursuant to the exercise of such demand rights or at the initiative of the Company), the Carlyle Shareholders may exercise piggyback rights to have included in such takedown Shares held by them that are registered on such
shelf. Notwithstanding the foregoing, Carlyle Shareholders may not demand a shelf takedown for an offering that will result in the imposition of a lockup on the Company and the Shareholders unless the Shares requested to be sold by the demanding
Carlyle Shareholders in such takedown have an aggregate market value (based on the most recent closing price of the Ordinary Shares at the time of the demand) of at least $50 million (or such lesser amount if all Shares held by the demanding
Carlyle Shareholders are requested to be sold). 
 (e) Right to Reload a Shelf. Upon the written request of a Carlyle Shareholder, the
Company will file and seek the effectiveness of a post-effective amendment to an existing shelf in order to register up to the number of Shares previously taken down off of such shelf and not yet “reloaded” onto such shelf. 

(f) Limitations on Demand and Piggyback Rights. 

(i) Any demand for the filing of a registration statement or for a registered offering or takedown will be subject to the
constraints of any applicable lockup arrangements, and such demand must be deferred until such lockup arrangements no longer apply. If a demand has been made for a non-shelf registered offering or for an
underwritten takedown, no further demands may be made so long as the related offering is still being pursued. Notwithstanding anything in this Agreement to the contrary, the Carlyle Shareholders will not have piggyback or other registration rights
with respect to registered primary offerings by the Company (i) covered by a Form S-8 registration statement or a successor form applicable to employee benefit-related offers and sales, (ii) where
the Shares are not being sold for cash or (iii) where the offering is a bona fide offering of securities other than Shares, even if such securities are convertible into or exchangeable or exercisable for Shares. 

(ii) The Company may postpone the filing of a demanded registration statement or suspend the effectiveness of any shelf
registration statement for a reasonable “blackout period” not in excess of 90 days if the Board of Directors of the Company determines that such registration or offering could materially interfere with a bona fide business or financing
transaction of the Company or is reasonably likely to require premature disclosure of information, the premature disclosure of which could materially and adversely affect the Company; provided that the Company shall not postpone the filing of a
demanded registration statement or suspend the effectiveness of any shelf registration statement pursuant to this Section 3.1(f)(ii) more than once in any 360 day period. The blackout period will end upon the earlier to occur of, (i) in
the case of a bona fide business or financing transaction, a date not later than 90 days from the date such deferral commenced, and (ii) in the case of disclosure of other non-public information, the
earlier to occur of (x) the filing by the Company of its next succeeding Form 10-K or Form 10-Q, or (y) the date upon which such information is otherwise
disclosed. 

  
 5 

 3.2 Notices, Cutbacks and Other Matters. 

(a) Notifications Regarding Registration Statements. In order for one or more Carlyle Shareholders to exercise their right to demand
that a registration statement be filed, they must so notify the Company in writing indicating the number of Shares sought to be registered and the proposed plan of distribution. The Company will keep the Carlyle Shareholders contemporaneously
apprised of all pertinent aspects of its pursuit of any registration, whether pursuant to a Carlyle Shareholder demand or otherwise, with respect to which a piggyback opportunity is available. Pending any required public disclosure and subject to
applicable legal requirements, the parties will maintain the confidentiality of these discussions. 
 (b) Notifications Regarding
Registration Piggyback Rights. Any Carlyle Shareholder wishing to exercise its piggyback rights with respect to a non-shelf registration statement must notify the Company and the other Carlyle Shareholders
of the number of Shares it seeks to have included in such registration statement. Such notice must be given as soon as practicable, but in no event later than 5:00 pm, New York City time, on the second trading day prior to (i) if applicable,
the date on which the preliminary prospectus intended to be used in connection with pre-effective marketing efforts for the relevant offering is expected to be finalized, and (ii) in any case, the date on
which the pricing of the relevant offering is expected to occur. No such notice is required in connection with a shelf registration statement, as Shares held by all Carlyle Shareholders will be included up to the applicable percentage (unless
otherwise requested by any Carlyle Shareholder). 
 (c) Notifications Regarding Demanded Underwritten Takedowns. 

(i) The Company will keep the Carlyle Shareholders contemporaneously apprised of all pertinent aspects of any underwritten
shelf takedown in order that they may have a reasonable opportunity to exercise their related piggyback rights. Without limiting the Company’s obligation as described in the preceding sentence, having a reasonable opportunity requires that the
Carlyle Shareholders be notified by the Company of an anticipated underwritten takedown (whether pursuant to a demand made by other Carlyle Shareholders or made at the Company’s own initiative) no later than 5:00 pm, New York City time, on
(i) if applicable, the second trading day prior to the date on which the preliminary prospectus or prospectus supplement intended to be used in connection with pre-pricing marketing efforts for such
takedown is finalized, and (ii) in all cases, the second trading day prior to the date on which the pricing of the relevant takedown occurs. 

(ii) Any Carlyle Shareholder wishing to exercise its piggyback rights with respect to an underwritten shelf takedown must
notify the Company and the other Carlyle Shareholders of the number of Shares it seeks to have included in such takedown. Such notice must be given as soon as practicable, but in no event later than 5:00 pm, New York City time, on (i) if
applicable, the trading day prior to the date on which the preliminary prospectus or prospectus supplement intended to be used in connection with marketing efforts for the relevant offering is expected to be finalized, and (ii) in all cases,
the trading day prior to the date on which the pricing of the relevant takedown occurs. 
 (iii) Pending any required public
disclosure and subject to applicable legal requirements, the parties will maintain appropriate confidentiality of their discussions regarding a prospective underwritten takedown. 

(d) Plan of Distribution, Underwriters and Counsel. If (1) a majority of the Shares proposed to be sold in an underwritten offering
through a non-shelf registration statement or through a shelf takedown are being sold by the Company for its own account and (2) such offering was initiated by the Company and not by any Carlyle
Stockholder, the Company will be entitled to determine the plan of distribution and select the managing underwriters for such offering. Otherwise, the Carlyle Shareholders holding a majority of the Shares requested to be included in such offering
will be entitled to determine the plan of distribution and select the managing underwriters, and such majority will also be entitled to select counsel for the selling Shareholders (which may be the same as counsel for the Company). In the case of a
shelf registration statement, the plan of distribution will provide as much flexibility as is reasonably possible, including with respect to resales by transferee Shareholders. 

  
 6 

 (e) Cutbacks. If the managing underwriters advise the Company and the selling
Shareholders that, in their opinion, the number of Shares requested to be included in an underwritten offering exceeds the amount that can be sold in such offering without adversely affecting the distribution of the Shares being offered, such
offering will include only the number of Shares that the underwriters advise can be sold in such offering. 
 (i) In the case
of a registered offering upon the demand of one or more Carlyle Shareholders, the selling Shareholders (including those Carlyle Shareholders exercising piggyback rights pursuant to Section 3.1(b)) collectively will have first priority and will
be subject to cutback pro rata based on the Initial Capital Interest of each such selling Shareholder (up to the number of Shares initially requested by them to be included in such offering). To the extent of any remaining capacity, all other
shareholders having similar registration rights will have second priority and will be subject to cutback pro rata based on the number of Shares initially requested by them to be included in such offering. Except as contemplated by the immediately
preceding two sentences, other selling shareholders (other than transferees to whom a Carlyle Shareholder has assigned its rights under this Agreement) will be included in an underwritten offering only with the consent of Carlyle Shareholders
holding a majority of the Shares being sold in such offering. 
 (ii) In the case of a registered offering upon the
initiative of the Company, the Company will have first priority. To the extent of any remaining capacity, the selling Carlyle Shareholders as a group, on the one hand, and all other shareholders having similar registration rights as a group, on the
other hand, will be subject to cutback pro rata based on the number of Shares initially requested by such group to be included in such offering. The selling Carlyle Shareholders will be subject to cutback pro rata, based on the Initial Capital
Interest of each such selling Carlyle Shareholder (up to the number of Shares initially requested by them to be included in such offering). Except as contemplated by the immediately preceding sentence, other shareholders (other than transferees to
whom a Carlyle Shareholder has assigned its rights under this Agreement) will be included in an underwritten offering only with the consent of a Carlyle Majority Interest. 

(f) Withdrawals. Even if Shares held by a Carlyle Shareholder have been part of a registered underwritten offering, such Carlyle
Shareholder may, no later than the time at which the public offering price and underwriters’ discount are determined with the managing underwriter, decline to sell all or any portion of the Shares being offered for its account. 

(g) Expenses. All expenses incurred in connection with any registration statement or registered offering covering Shares held by Carlyle
Shareholders, including, without limitation, all registration and filing fees, printing expenses (including printing certificates for the Shares in a form eligible for deposit with the Depository Trust Company and printing preliminary, supplemental
and final prospectuses), word processing, duplicating, telephone and facsimile expenses, messenger and delivery expenses, transfer taxes, expenses incurred in connection with promotional efforts or “roadshows”, fees and disbursements of
counsel (including the fees and disbursements of outside counsel for Carlyle Shareholders (which may be the same as counsel for the Company) and fees and disbursements of counsel to the underwriters with respect to “blue sky” qualification
of such Shares and their determination for eligibility for investment under the laws of the various jurisdictions and in connection with any filing with, and clearance of any offering by, FINRA (up to the cap on such fees included in any applicable
underwriting 

  
 7 

 
agreement)) and of the independent certified public accountants (including with respect to the preparation of customary financial statements required to be included in any offering document, the
provision of any customary comfort letters and any the conduct of special audits required by, or incidental to, such registration), and the expense of qualifying such Shares under state blue sky and non-U.S.
securities laws, will be borne by the Company. However, underwriters’, brokers’ and dealers’ discounts and commissions applicable to Shares sold for the account of a Carlyle Shareholder will be borne by such Carlyle Shareholder. 

3.3 Facilitating Registrations and Offerings. 

(a) General. If the Company becomes obligated under this Agreement to facilitate a registration and offering of Shares on behalf of
Carlyle Shareholders, the Company will do so with the same degree of care and dispatch as would reasonably be expected in the case of a registration and offering by the Company of Shares for its own account. Without limiting this general obligation,
the Company will fulfill its specific obligations as described in this Section 3.3. 
 (b) Registration Statements. In connection
with each registration statement that is demanded by Carlyle Shareholders or as to which piggyback rights otherwise apply, the Company will: 

(i) prepare and file (or confidentially submit) with the SEC a registration statement covering the applicable Shares,
(ii) prepare and file (or confidentially submit) such amendments or supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for a period ending
when all of the securities covered by such registration statement have been disposed of in accordance with the intended methods of distribution by the sellers thereof set forth in such registration statement (but not in any event before the
expiration of any longer period required under the Securities Act or, if such registration statement relates to an underwritten public offering, such longer period as in the opinion of counsel for the underwriters a prospectus is required by law to
be delivered in connection with the sale of Shares by an underwriter or dealer), (iii) seek the effectiveness thereof, and (iv) file with the SEC prospectuses and prospectus supplements as may be required, all in consultation with the Carlyle
Shareholders and as reasonably necessary in order to permit the offer and sale of the such Shares in accordance with the applicable plan of distribution; 

(ii) (1) within a reasonable time prior to the filing of any registration statement, any prospectus, any amendment to a
registration statement, amendment or supplement to a prospectus or any free writing prospectus, provide copies of such documents to the selling Carlyle Shareholders and to the underwriter or underwriters of an underwritten offering, if applicable,
and to their respective counsel; fairly consider such reasonable changes in any such documents prior to or after the filing thereof as the counsel to the Carlyle Shareholders or the underwriter or the underwriters may request; and make such of the
representatives of the Company as shall be reasonably requested by the selling Carlyle Shareholders or any underwriter available for discussion of such documents; 

(2) within a reasonable time prior to the filing of any document which is to be incorporated by reference into a registration statement or a
prospectus, provide copies of such document to counsel for the Carlyle Shareholders and underwriters; fairly consider such reasonable changes in such document prior to or after the filing thereof as counsel for such Carlyle Shareholders or such
underwriter shall request; and make such of the representatives of the Company as shall be reasonably requested by such counsel available for discussion of such document; 

  
 8 

 (iii) cause each registration statement and the related prospectus and any
amendment or supplement thereto, as of the effective date of such registration statement, amendment or supplement and during the distribution of the registered Shares (x) to comply in all material respects with the requirements of the
Securities Act and the rules and regulations of the SEC and (y) not to contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading;

 (iv) notify each Carlyle Shareholder promptly, and, if requested by such Carlyle Shareholder, confirm such advice in
writing, (i) when a registration statement has become effective and when any post-effective amendments and supplements thereto become effective if such registration statement or post-effective amendment is not automatically effective upon
filing pursuant to Rule 462, (ii) of the issuance by the SEC or any state or non-U.S. securities authority of any stop order, injunction or other order or requirement suspending the effectiveness of a
registration statement or the initiation of any proceedings for that purpose, (iii) if, between the effective date of a registration statement and the closing of any sale of securities covered thereby pursuant to any agreement to which the
Company is a party, the representations and warranties of the Company contained in such agreement cease to be true and correct in all material respects or if the Company receives any notification with respect to the suspension of the qualification
of the Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose, and (iv) of the happening of any event during the period a registration statement is effective as a result of which such
registration statement or the related prospectus contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, if required by
applicable law, prepare and file a supplement or amendment to such registration statement or prospectus so that, as thereafter delivered to the purchasers of Shares registered thereby, such registration statement or prospectus will not contain an
untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading; 
 (v)
furnish counsel for each underwriter, if any, and for the Carlyle Shareholders copies of any correspondence with the SEC or any state securities authority relating to the registration statement or prospectus; 

(vi) otherwise comply with all applicable rules and regulations of the SEC, including making available to its security holders
an earnings statement covering at least 12 months which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder (or any similar provision then in force); 

(vii) use all reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of a registration statement
at the earliest possible time; 
 (c) Non-Shelf Registered Offerings and Shelf Takedowns. In
connection with any non-shelf registered offering or shelf takedown that is demanded by Carlyle Shareholders or as to which piggyback rights otherwise apply, the Company will: 

(i) cooperate with the selling Carlyle Shareholders and the sole underwriter or managing underwriter of an underwritten
offering Shares, if any, to facilitate the timely preparation and delivery of certificates representing the Shares to be sold and not bearing any restrictive legends; and enable such Shares to be in such denominations (consistent with the provisions
of the governing documents thereof) and registered in such names as the selling Carlyle Shareholders or the sole underwriter or managing underwriter of an underwritten offering of Shares, if any, may reasonably request at least five days prior to
any sale of such Shares; 

  
 9 

 (ii) furnish to each Carlyle Shareholder and to each underwriter, if any,
participating in the relevant offering, without charge, as many copies of the applicable prospectus, including each preliminary prospectus, and any amendment or supplement thereto and such other documents as such Carlyle Shareholder or underwriter
may reasonably request in order to facilitate the public sale or other disposition of the Shares; the Company hereby consents to the use of the prospectus, including each preliminary prospectus or prospectus supplement, by each such Carlyle
Shareholder and underwriter in connection with the offering and sale of the Shares covered by the prospectus, the preliminary prospectus or prospectus supplement; 

(iii) (i) use all reasonable efforts to register or qualify the Shares being offered and sold, no later than the time the
applicable registration statement becomes effective, under all applicable state securities or “blue sky” laws of such jurisdictions as each underwriter, if any, or any Carlyle Shareholder holding Shares covered by a registration statement,
shall reasonably request; (ii) use all reasonable efforts to keep each such registration or qualification effective during the period such registration statement is required to be kept effective; (iii) comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in the registration statement and
(iv) do any and all other acts and things which may be reasonably necessary or advisable to enable each such underwriter, if any, and Carlyle Shareholder to consummate the disposition in each such jurisdiction of such Shares owned by such
Carlyle Shareholder; provided, however, that the Company shall not be obligated to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to consent to be subject to general
service of process (other than service of process in connection with such registration or qualification or any sale of Shares in connection therewith) in any such jurisdiction where it would not otherwise be required to qualify but for this
subparagraph (iv) or subject itself to taxation in any such jurisdiction; 
 (iv) (i) cause all Shares being sold
to be qualified for inclusion in or listed on Nasdaq or any other U.S. securities exchange on which Shares issued by the Company are then so qualified or listed if so requested by the Carlyle Shareholders, or if so requested by the underwriter or
underwriters of an underwritten offering of Shares, if any and arrange for at least two market makers to register as such with respect to the Shares with FINRA, (ii) comply (and continue to comply) with the requirements of any self-regulatory
organization applicable to the Company, including without limitation all corporate governance requirements, (iii) use its best efforts to cause Shares covered by such registration statement to be registered with or approved by such other
governmental agencies or authorities as may be necessary to enable the sellers thereof to consummate the disposition of such Shares and (iv) use best efforts to provide a transfer agent and registrar for all Shares to be sold by the Carlyle
Shareholders not later than the effective date of such registration statement; 
 (v) cooperate and assist in any filings
required to be made with FINRA and in the performance of any due diligence investigation by any underwriter in an underwritten offering; 

(vi) use all reasonable efforts to facilitate the distribution and sale of any Shares to be offered pursuant to this Agreement,
including without limitation by making road show presentations, holding meetings with and making calls to potential investors and taking such other actions as shall be requested by the Carlyle Shareholders or the lead managing underwriter of an
underwritten offering; 

  
 10 

 (vii) enter into customary agreements (including, in the case of an
underwritten offering, underwriting agreements in customary form, and including provisions with respect to indemnification and contribution in customary form and consistent with the provisions relating to indemnification and contribution contained
herein) and take all other customary and appropriate actions in order to expedite or facilitate the disposition of such Shares in connection therewith, including: 

(1) make such representations and warranties to the selling Shareholders and the underwriters, if any, in form, substance and scope as are
customarily made by issuers to underwriters in similar underwritten offerings; 
 (2) obtain opinions of counsel to the Company in all
relevant jurisdictions and updates thereof (which counsel and opinions (in form, scope and substance) shall be reasonably satisfactory to the lead managing underwriter, if any) addressed to each selling Shareholder and the underwriters, if any,
covering the matters and jurisdictions customarily covered in opinions requested in sales of securities or underwritten offerings and such other matters as may be reasonably requested by such Shareholders and underwriters; 

(3) obtain “cold comfort” letters and updates thereof from the Company’s independent certified public accountants addressed to
the selling Shareholders, if permissible, and the underwriters, if any, which letters shall be customary in form and shall cover matters of the type customarily covered in “cold comfort” letters to underwriters in connection with primary
underwritten offerings; 
 (4) to the extent requested by the Carlyle Shareholders, cause the Company’s directors and executive
officers to enter into lock-up agreements in customary form; and 
 (5) to the extent requested and
customary for the relevant transaction, enter into a securities sales agreement with the Carlyle Shareholders providing for, among other things, the appointment of such representative as agent for the selling Carlyle Shareholders for the purpose of
soliciting purchases of Shares, which agreement shall be customary in form, substance and scope and shall contain customary representations, warranties and covenants. 

The above shall be done at such times as customarily occur in similar registered offerings or shelf takedowns. 

(viii) take all actions to ensure that any free writing prospectus utilized in connection with any registration or offering
hereunder complies in all material respects with the Securities Act in relation to the circulation of a prospectus, is filed in accordance with the Securities Act, is retained in accordance with the Securities Act and, when taken together with the
related prospectus, prospectus supplement and related documents, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading; 
 (ix) permit any Carlyle Stockholder that, in its sole exclusive judgment, might be deemed to be an
underwriter or a controlling person of the Company, to participate in the preparation of such registrations statement and to allow such Carlyle Stockholder to provide language for insertion therein, in form and substance satisfactory to the Company,
which in the reasonable judgment of such Carlyle Stockholder and its counsel should be included; 

  
 11 

 (x) use best efforts to (i) make Form
S-3 available for the sale of Shares and (ii) prevent the issuance of any stop order suspending the effectiveness of a registration statement, or the issuance of any order suspending or preventing the use
of any related prospectus or suspending the qualification of any Shares included in such registration statement for sale in any jurisdiction, and in the event any such order is issued, use best efforts to obtain promptly the withdrawal of such
order; 
 (xi) if requested by any managing underwriter and reasonably available, include in any prospectus or prospectus
supplement updated financial or business information for the Company’s most recent period or current quarterly period (including estimated results or ranges of results) if required for purposes of marketing the offering in the view of the
managing underwriter; 
 (xii) take no direct or indirect action prohibited by Regulation M under the Exchange Act; 

(xiii) cooperate with each Carlyle Stockholder covered by the registration statement and each underwriter or agent
participating in the disposition of such Shares and their respective counsel in connection with the preparation and filing of applications, notices, registrations and responses to requests for additional information with FINRA, Nasdaq or any other
national securities exchange on which the Shares are or are to be listed, and to the extent required by the rules and regulations of FINRA, retain a Qualified Independent Underwriter acceptable to the managing underwriter; 

(xiv) if the Company files an automatic shelf registration statement covering any Shares, use its best efforts to remain a WKSI
(and not become an ineligible issuer (as defined in Rule 405 under the Securities Act)) during the period during which such automatic shelf registration statement is required to remain effective; 

(xv) if the Company does not pay the filing fee covering the Shares at the time an automatic shelf registration statement is
filed, pay such fee at such time or times as the Shares are to be sold; 
 (xvi) if the automatic shelf registration
statement has been outstanding for at least three years, at the end of the third year, refile a new automatic shelf registration statement covering the Shares, and, if at any time when the Company is required to
re-evaluate its WKSI status the Company determines that it is not a WKSI, use its best efforts to refile the shelf registration statement on Form S-3 and, if such form
is not available, Form S-1 and keep such registration statement effective during the period during which such registration statement is required to be kept effective; and 

(xvii) if the Company plans to file any automatic shelf registration statement for the benefit of the holders of any of its
securities other than the Carlyle Shareholders, and the Carlyle Shareholders do not request that their Shares be included in such shelf registration statement, the Company agrees that, at the request of the Carlyle Majority Interest, include in such
automatic shelf registration statement such disclosures as may be required by Rule 430B in order to ensure that the Carlyle Shareholders may be added to such shelf registration statement at a later time through the filing of a prospectus supplement
rather than a post-effective amendment (and if the Company has filed any automatic shelf registration statement for the benefit of the holders of any of its securities other than the Carlyle Shareholders, the Company shall, at the request of the
Carlyle Majority Interest, file any post-effective amendments necessary to include therein all disclosure and language necessary to ensure that the Carlyle Shareholders may be added to such Shelf Registration Statement). 

  
 12 

 (d) Due Diligence. In connection with each registration and offering of Shares to be
sold by Carlyle Shareholders, the Company will, in accordance with customary practice, make available for inspection by representatives of the Carlyle Shareholders and underwriters and any counsel or accountant retained by such Carlyle Shareholder
or underwriters all relevant financial and other records, pertinent corporate documents and properties of the Company and cause appropriate officers, managers and employees of the Company to supply all information reasonably requested by any such
representative, underwriter, counsel or accountant in connection with their due diligence exercise. 
 (e) Information from
Shareholders. Each Carlyle Shareholder that holds Shares covered by any registration statement will furnish to the Company such information regarding itself as is required to be included in the registration statement, the ownership of Shares by
such Carlyle Shareholder and the proposed distribution by such Carlyle Shareholder of such Shares as the Company may from time to time reasonably request in writing. 

3.4 Indemnification. 
 (a)
Indemnification by the Company. In the event of any registration under the Securities Act by any registration statement of Shares held by Carlyle Shareholders, the Company will hold harmless Carlyle Shareholders, any such Carlyle
Shareholder’s officers, directors, employees, agents, fiduciaries, shareholders, managers, partners, members, affiliates, direct and indirect equityholders, consultants and representatives, and any successors and assigns thereof, and each
underwriter of such securities and each other person, if any, who controls any Carlyle Shareholder or such underwriter within the meaning of the Securities Act (collectively, the “Indemnified Parties”), against any losses, claims,
actions, damages, liabilities or expenses (including with respect to actions or proceedings, whether commenced or threatened, and including reasonable attorney fees and expenses) (collectively, “Losses”), joint or several, to which
Carlyle Shareholders or such underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such Losses arise out of or are based upon (i) any untrue or alleged untrue statement of material fact contained
in (A) any registration statement, prospectus, preliminary prospectus or free writing prospectus, or any amendment thereof or supplement thereto or (B) any application or other document or communication (in this Section 3.4,
collectively called an “application”) executed by or on behalf of the Company or based upon written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify any securities covered by such
registration under the “blue sky” or securities laws thereof, (ii) any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading or (iii) any
violation or alleged violation by the Company of the Securities Act or any other similar federal or state securities laws or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the
Company in connection with any such registration, qualification or compliance; and will reimburse any such Indemnified Person for any legal or any other expenses reasonably incurred by them in connection with investigating or defending any such
Losses; provided, however, that the Company shall not be liable to any such Indemnified Person in any such case to the extent that any such Losses arise out of or are based upon an untrue statement or alleged untrue statement or omission or alleged
omission made in such registration statement, prospectus, preliminary prospectus or free writing prospectus or any amendment or supplement thereto, or in any application, in reliance upon and in conformity with information furnished to the Company
through a written instrument duly executed by such Indemnified Person specifically for use in the preparation thereof. 

  
 13 

 (b) Indemnification by Carlyle Shareholders. Each Carlyle Shareholder will indemnify
and hold harmless (in the same manner and to the same extent as set forth in Section 3.4(a)) the Company, its officers, directors, employees, agents and representatives, and each Person who controls the Company (within the meaning of the
Securities Act), with respect to Losses (as determined by a final and unappealable judgment, order or decree of a court of competent jurisdiction) arising from (i) any statement or omission from such registration statement, or any amendment or
supplement to it, if such statement or omission was made in reliance upon and in conformity with information furnished to the Company through a written instrument duly executed by such Carlyle Shareholder specifically regarding such Carlyle
Shareholder for use in the preparation of such registration statement or amendment or supplement, and (ii) compliance by such Carlyle Shareholder with applicable laws in effecting the sale or other disposition of the securities covered by such
registration statement. 
 (c) Indemnification Procedures. Promptly after receipt by an indemnified party of notice of the
commencement of any action involving a claim referred to in Section 3.4(a) and Section 3.4(b), the indemnified party will, if a resulting claim is to be made or may be made against and indemnifying party, give written notice to the
indemnifying party of the commencement of the action. The failure of any indemnified party to give notice shall not relieve the indemnifying party of its obligations in this Section 3.4, except to the extent that the indemnifying party is
actually prejudiced by the failure to give notice. If any such action is brought against an indemnified party, the indemnifying party will be entitled to participate in and to assume the defense of the action with counsel reasonably satisfactory to
the indemnified party, and after notice from the indemnifying party to such indemnified party of its election to assume defense of the action, the indemnifying party will not be liable to such indemnified party for any legal or other expenses
incurred by the latter in connection with the action’s defense. An indemnified party shall have the right to employ separate counsel in any action or proceeding and participate in the defense thereof, but the fees and expenses of such counsel
shall be at such indemnified party’s expense unless (a) the employment of such counsel has been specifically authorized in writing by the indemnifying party, which authorization shall not be unreasonably withheld, (ii) the
indemnifying party has not assumed the defense and employed counsel reasonably satisfactory to the indemnified party within 30 days after notice of any such action or proceeding, or (iii) the named parties to any such action or proceeding
(including any impleaded parties) include the indemnified party and the indemnifying party and the indemnified party shall have been advised by such counsel that there may be one or more legal defenses available to the indemnified party that are
different from or additional to those available to the indemnifying party (in which case the indemnifying party shall not have the right to assume the defense of such action or proceeding on behalf of the indemnified party), it being understood,
however, that the indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the
reasonable fees and expenses of more than one separate firm of attorneys (in addition to all local counsel which is necessary, in the good faith opinion of both counsel for the indemnifying party and counsel for the indemnified party in order to
adequately represent the indemnified parties) for the indemnified party and that all such fees and expenses shall be reimbursed as they are incurred upon written request and presentation of invoices. Whether or not a defense is assumed by the
indemnifying party, the indemnifying party will not be subject to any liability for any settlement made without its consent (such consent not to be unreasonably withheld, delayed or conditioned). No indemnifying party will consent to entry of any
judgment or enter into any settlement which (i) does not include as an unconditional term the giving by the claimant or plaintiff, to the indemnified party, of a release from all liability in respect of such claim or litigation or
(ii) involves the imposition of equitable remedies or the imposition of any non-financial obligations on the indemnified party. 

(d) Contribution. If the indemnification required by this Section 3.4 from the indemnifying party is unavailable to or insufficient
to hold harmless an indemnified party in respect of any indemnifiable Losses, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Losses in such proportion as is appropriate to
reflect (i) the relative benefit of the indemnifying and indemnified parties and (ii) if the allocation in clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect the relative benefit referred to
in clause (i) 

  
 14 

 
and also the relative fault of the indemnified and indemnifying parties, in connection with the actions which resulted in such Losses, as well as any other relevant equitable considerations. The
relative fault of the indemnifying party and the indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact, has been made by, or
relates to information supplied by, such indemnifying party or parties, and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of
the Losses referred to above shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with any investigation or proceeding. The Company and Carlyle Shareholders agree that it would not be just
and equitable if contribution pursuant to this Section 3.4(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the prior provisions of this
Section 3.4(d). Notwithstanding the provisions of this Section 3.4(d), no Carlyle Shareholder shall be required to contribute any amount in excess of the amount by which the net proceeds from the sale of the securities by such Carlyle
Shareholder exceeds the amount of any damages which the indemnifying party has otherwise been required to pay by reason of an untrue statement or omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such a fraudulent misrepresentation. 
 (e) Non-Exclusive Remedy. The indemnification and contribution provided for under this Agreement will be in addition to any other rights to indemnification or contribution that any indemnified party may have
pursuant to law or contract (and the Company and its subsidiaries shall be considered the indemnitors of first resort in all such circumstances to which this Section 3 applies) and will remain in full force and effect
regardless of any investigation made by or on behalf of the indemnified party or any officer, director or controlling Person of such indemnified party and will survive the transfer of Shares and the termination or expiration of this Agreement. 

3.5 Rule 144. If the Company is subject to the requirements of Section 13, 14 or 15(d) of the Exchange Act, the Company covenants
that it will file any reports required to be filed by it under the Securities Act and the Exchange Act (or, if the Company is subject to the requirements of Section 13, 14 or 15(d) of the Exchange Act but is not required to file such reports,
it will, upon the request of any Carlyle Shareholder, make publicly available such information) and it will take such further action as any Carlyle Shareholder may reasonably request, so as to enable such Carlyle Shareholder to sell Shares without
registration under the Securities Act within the limitation of the exemptions provided by (a) Rule 144 under the Securities Act, as such Rule may be amended from time to time, or (b) any similar rule or regulation hereafter adopted by the
SEC. Upon the request of any Carlyle Shareholder, the Company will deliver to such Carlyle Shareholder a written statement as to whether it has complied with such requirements. Furthermore, the Company shall use its reasonable best efforts to
facilitate any sale by a Carlyle Shareholder under Rule 144, including delivery of any legal opinions and instruction letters required by the Company’s transfer agent and such other documentation as may be reasonably requested by the Carlyle
Shareholder or its broker in connection with such sales. 
 SECTION IV. MISCELLANEOUS PROVISIONS 

4.1 Information and Access Rights. 

(a) Available Financial Information. Upon written request, the Company will deliver, or will cause to be delivered, to each Carlyle
Shareholder (until such time as such Carlyle Shareholder shall cease to own any Shares): 

  
 15 

 (i) as soon as available after the end of each month and in any event within
30 days thereafter, a consolidated balance sheet of the Company and its subsidiaries as of the end of such month and consolidated statements of operations, income, cash flows, retained earnings and shareholders’ equity of the Company and its
subsidiaries, for each month and for the current fiscal year of the Company to date, prepared in accordance with GAAP (subject to normal year-end audit adjustments and the absence of notes thereto), together
with a comparison of such statements to the corresponding periods of the prior fiscal year and to the Company’s business plan then in effect and approved by the Board of Directors; 

(ii) an annual budget, a business plan and financial forecasts for the Company for the fiscal year of the Company (the
“Annual Budget”), no later than three (3) business days after the approval thereof by the Board of Directors (but no later than March 31 of such fiscal year), in such manner and form as approved by the Board of Directors,
which shall include at least a projection of income and a projected cash flow statement for each fiscal quarter in such fiscal year and a projected balance sheet as of the end of each fiscal quarter in such fiscal year, in each case prepared in
reasonable detail, with appropriate presentation and discussion of the principal assumptions upon which such budgets and projections are based, which shall be accompanied by the statement of the chief executive officer or chief financial officer or
equivalent officer of the Company to the effect that such budget and projections are based on reasonable and good faith estimates and assumptions made by the management of the Company for the respective periods covered thereby; it being recognized
by such holders that such budgets and projections as to future events are not to be viewed as facts and that actual results during the period or periods covered by them may differ from the projected results. Any material changes in such Annual
Budget shall be delivered to the Carlyle Shareholders as promptly as practicable after such changes have been approved by the Board of Directors; 

(iii) as soon as available after the end of each fiscal year of the Company, and in any event within 90 days thereafter,
(A) the annual financial statements required to be filed by the Company pursuant to the Exchange Act or (B) a consolidated balance sheet of the Company and its subsidiaries as of the end of such fiscal year, and consolidated statements of
income, retained earnings and cash flows of the Company and its subsidiaries for such year, prepared in accordance with GAAP and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and
accompanied by the opinion of independent public accountants of recognized national standing selected by the Company, and a Company-prepared comparison to the Company’s Annual Budget for such year as approved by the Board of Directors (the
“Annual Financial Statements”); and 
 (iv) as soon as available after the end of the first, second and
third quarterly accounting periods in each fiscal year of the Company, and in any event within 45 days thereafter, (A) the quarterly financial statements required to be filed by the Company pursuant to the Exchange Act or (B) a
consolidated balance sheet of the Company and its subsidiaries as of the end of each such quarterly period, and consolidated statements of income, retained earnings and cash flows of the Company and its subsidiaries for such period and for the
current fiscal year to date, prepared in accordance with GAAP (subject to normal year-end audit adjustments and the absence of notes thereto) and setting forth in comparative form the figures for the
corresponding periods of the previous fiscal year and to the Company’s Annual Budget then in effect as approved by the Board of Directors, all of the information to be provided pursuant to this Section 4.1(a)(iv) in reasonable detail and
certified by the principal financial or accounting officer of the Company. 
 In addition to the foregoing, the Company covenants and agrees
to provide periodic updates to each Carlyle Shareholder during the course of the preparation of the Annual Budget and to keep the Carlyle Shareholders reasonably informed as to its progress, status and the budgeted items set forth therein.
Notwithstanding anything to the contrary in Section 4.1(a), the Company’s obligations thereunder shall be 

  
 16 

 
deemed satisfied to the extent that such information is provided by (A) providing the financial statements of any wholly-owned subsidiary of the Company to the extent such financial
statements reflect the entirety of the operations of the business or (B) in the case of Section 4.1(a)(iii) and Section 4.1(a)(iv), filing such financial statements of the Company or any wholly-owned subsidiary of the Company whose
financial statements satisfy the requirements of clause (A), as applicable, with the Securities and Exchange Commission on EDGAR or in such other manner as makes them publicly available. The Company’s obligation to furnish the materials
described in Section 4.1(a)(i), Section 4.1(a)(iii) and Section 4.1(a)(iv), shall be satisfied so long as it transmits such materials to the requesting Carlyle Shareholders within the time periods specified therein, notwithstanding
that such materials may actually be received after the expiration of such periods. 
 (b) Tax Information. Promptly upon request by
any Carlyle Shareholder, the Company will, at the Company’s expense, prepare and deliver to such Carlyle Shareholder any information and certified statement that such Carlyle Shareholder determines to be necessary for such Carlyle Shareholder
(or its direct or indirect owners) to comply with obligations for tax reporting or tax withholding with respect to an investment (direct or indirect) in the Company or any of its subsidiaries. For the avoidance of doubt, such a request by any
Carlyle Shareholder may require the Company, (i) for purposes of Section 301 of the United States Internal Revenue Code of 1986, as amended (the “Code”), to prepare financial statements pursuant to the principles of
“earnings and profits” within the meaning of United States federal income tax law and to determine the amount of any “dividend” within the meaning of Section 316 of the Code, (ii) for purposes of Section 951 and
Section 951A of the Code, to determine whether the Company or any of its subsidiaries is a “controlled foreign corporation” within the meaning of Section 957 of the Code, to prepare financial statements pursuant to the principles
of “earnings and profits” within the meaning of United States federal income tax law, and to determine the amount of any “subpart F income” within the meaning of Section 952 of the Code and any “global intangible low-taxed income” income within the meaning of Section 951A of the Code, and (iii) for purposes of Section 1291 of the Code and the election under Section 1295 of the Code, to determine
whether the Company or any of its subsidiaries is a “passive foreign investment company” within the meaning of Section 1297 of the Code and to provide the information described in Treasury Regulations
Section 1.1295-1(g). 
 (c) Other Information. The Company covenants and agrees to
deliver to each Carlyle Shareholder, upon written request, until such time as such Carlyle Shareholder shall cease to own any Shares, with reasonable promptness, such other information and data (including such information and reports made available
to any lender of the Company or any of its subsidiaries under any credit agreement or otherwise) with respect to the Company and each of its subsidiaries as from time to time may be reasonably requested by any such Carlyle Shareholder. Each such
Carlyle Shareholder, until such time as such Carlyle Shareholder shall cease to own any Shares, shall have access to such other information concerning the Company’s business or financial condition and the Company’s management as may be
reasonably requested, including such information as may be necessary to comply with regulatory, tax or other governmental filings. 
 (d)
Access. The Company shall, and shall cause its subsidiaries, officers, directors, employees, auditors and other agents to (a) afford the Carlyle Shareholders and their officers, employees, auditors and other agents, during normal
business hours and upon reasonable notice, at all reasonable times to the Company’s and its subsidiaries’ officers, employees, auditors, legal counsel, properties, offices, plants and other facilities and to all books and records, and
(b) afford the Carlyle Shareholders and their officers, employees, auditors and other agents the opportunity to discuss the affairs, finances and accounts of the Company and its subsidiaries with their respective officers from time to time as
each such Carlyle Shareholder may reasonably request, in each case, until such time as such Carlyle Shareholder shall cease to own any Shares. 

  
 17 

 4.2 Confidentiality. Each Shareholder agrees that it will keep confidential and will
not disclose, divulge or use for any purpose, other than to monitor its investment in the Company and its subsidiaries, any confidential information obtained from the Company pursuant to Section 4.1, unless such confidential information
(a) is known or becomes known to the public in general (other than as a result of a breach of any confidentiality obligation by such Shareholder or its affiliates), (b) is or has been independently developed or conceived by such Shareholder
without use of the Company’s confidential information or (c) is or has been made known or disclosed to such Shareholder by a third party (other than an Affiliate of such Shareholder) without a breach of any confidentiality obligations such
third party may have to the Company that is known to such Shareholder; provided, that, a Shareholder may disclose confidential information (i) to its attorneys, accountants, consultants and other professional advisors to the
extent necessary to obtain their services in connection with monitoring its investment in the Company, (ii) to any prospective purchaser of any Shares from such Shareholder as long as such prospective purchaser agrees to be bound by the
provisions of this Section 4.2 as if a Shareholder, (iii) to any Affiliate, partner, member, limited partners, prospective partners or related investment fund of such Shareholder and their respective directors, employees, consultants and
representatives, in each case in the ordinary course of business (provided that the recipients of such confidential information are subject to a customary confidentiality and non-disclosure obligation), (iv)
as may be reasonably determined by such Shareholder to be necessary in connection with such Shareholder’s enforcement of its rights in connection with this Agreement or its investment in the Company and its subsidiaries, or (v) as may
otherwise be required by law or legal, judicial or regulatory process. 
 4.3 Reliance. Each covenant and agreement made by a party in
this Agreement or in any certificate, instrument or other document delivered pursuant to this Agreement is material, shall be deemed to have been relied upon by the other parties and shall remain operative and in full force and effect after the
Effective Date regardless of any investigation. This Agreement shall not be construed so as to confer any right or benefit upon any Person other than the parties hereto and their respective successors and permitted assigns. 

4.4 Access to Agreement; Amendment and Waiver; Actions of the Board. For so long as this Agreement shall be in effect, this Agreement
shall be made available for inspection by any Shareholder at the principal executive offices of the Company. Any party may waive in writing any provision hereof intended for its benefit, provided, that, in the case of any waiver by the Company, such
waiver is consented to in writing by the Carlyle Majority Interest. No failure or delay on the part of any party in exercising any right, power or remedy hereunder shall operate as a waiver thereof. The remedies provided for herein are cumulative
and are not exclusive of any remedies that may be available to any party at law or in equity or otherwise. This Agreement may be amended only with the prior written consent of the Carlyle Majority Interest and the Company. Any consent given as
provided in the preceding sentence shall be binding on all parties. Further, with the prior written consent of the Carlyle Majority Interest and the Company, at any time hereafter Permitted Transferees may be made parties hereto, with any such
additional parties shall be treated as “Shareholders” for all purposes hereunder, by executing a counterpart signature page in the form attached as Exhibit A hereto, which signature page shall be attached to this Agreement and become a
part hereof without any further action of any other party hereto. 
 4.5 Notices. All notices, requests, demands and other
communications provided for hereunder shall be in writing and mailed (by first class registered or certified mail, postage prepaid), sent by express overnight courier service, or delivered to the applicable party at the respective address indicated
below: 

  
 18 

 If to the Company: 

c/o Ortho-Clinical Diagnostics, Inc. 

1001 Route 202 
 Raritan, NJ 08869

 Attention: Michael A. Schlesinger 

Facsimile: (844) 892-5398 

With a copy (which shall not constitute notice): 

Latham & Watkins LLP 

555 Eleventh Street, N.W. 

Washington, D.C. 20004 

Attention: Daniel T. Lennon; David I. Brown 

Facsimile: (202) 637-2201 

If to the Carlyle Shareholders: 

c/o The Carlyle Group 
 520
Madison Avenue 
 42nd Floor 

New York, NY 10022 
 Attention:
Stephen H. Wise 
 Facsimile: (212) 893-4901 

With a copy (which shall not constitute notice): 

Latham & Watkins LLP 

555 Eleventh Street, N.W. 

Washington, D.C. 20004 

Attention: Daniel T. Lennon; David I. Brown 

Facsimile: (202) 637-2201 

If to any other Shareholder: 

At such Person’s address for notice as set forth in the books and records of the Company, or, as to each of the foregoing, at such other
address as shall be designated by a party in a written notice to other parties complying as to delivery with the terms of this Section 4.5. All such notices, requests, demands and other communications shall, when mailed, telegraphed or sent,
respectively, be effective (i) two days after being deposited in the mail or (ii) one day after being deposited with the express overnight courier service, respectively, addressed as aforesaid. 

4.6 Counterparts. This Agreement may be executed in two or more counterparts, and delivered via facsimile, .pdf or other electronic
transmission, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. 
 4.7
Remedies; Severability. It is specifically understood and agreed that any breach of the provisions of this Agreement by any party will result in irreparable injury to the other parties, that the remedy at law alone will be an inadequate
remedy for such breach, and that, in addition to any other legal or equitable remedies which they may have, such other parties may enforce their respective rights by actions for specific performance or injunctive relief (to the extent permitted at
law or in equity). If any one or more of the provisions of this Agreement, or the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any
such provision in every other respect and of the remaining provisions contained herein are not to be in any way impaired thereby, it being intended that all of the rights and privileges of the parties be enforceable to the fullest extent permitted
by law. 

  
 19 

 4.8 Entire Agreement. This Agreement constitutes the entire agreement of the Parties
with respect to the subject matter hereof. 
 4.9 Termination. This Agreement shall terminate on the earlier of (i) the election
of the Carlyle Majority Interest or (ii) such date as the Carlyle Shareholders, in the aggregate, cease to hold any Shares; provided that notwithstanding any such termination, Section 3.4 shall survive any expiration or termination of this
Agreement. Termination of this Agreement shall not relieve any party for the breach of any obligations under this Agreement prior to such termination. 

4.10 Governing Law. This Agreement is to be construed and enforced in accordance with the laws of the State of Delaware, without giving
effect to its principles or rules of conflict of laws to the extent such principles or rules are not mandatorily applicable by statute and would require or permit the application of the laws of another jurisdiction. 

4.11 Successors and Assigns; Beneficiaries. This Agreement shall be binding upon and inure to the benefit of the parties and the
respective successors and assigns of the parties as contemplated herein. Any successor to the Company by way of merger or otherwise must specifically agree to be bound by the terms hereof as a condition of such succession. 

4.12 Consent to Jurisdiction; Specific Performance; WAIVER OF JURY TRIAL. 

(a) Each of the parties hereto irrevocably and unconditionally consents to the sole and exclusive jurisdiction of the state and federal courts
located in Wilmington, Delaware to resolve all disputes, claims or controversies arising out of or relating to this Agreement or any other agreement executed and delivered pursuant to or in connection with this Agreement or the negotiation, breach,
validity, termination or performance hereof and thereof or the transactions contemplated hereby and thereby and agrees that it will not bring any such action in any court other than the federal or state courts located in Wilmington, Delaware. Each
party further irrevocably waives any objection to proceeding in such courts based upon lack of personal jurisdiction or to the laying of venue in such courts and further irrevocably and unconditionally waives and agrees not to make a claim that such
courts are an inconvenient forum. Each of the parties hereto hereby consents to service of process by registered mail at the address to which notices are to be given as provided in Section 4.5. Each of the parties hereto agrees that its or his
submission to jurisdiction and its or his consent to service of process by mail is made for the express benefit of the other parties hereto. The choice of forum set forth in this Section shall not be deemed to preclude the enforcement of any
judgment of a Delaware federal or state court, or the taking of any action under this Agreement to enforce such a judgment, in any other appropriate jurisdiction. 

(b) The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions
of this Agreement, this being in addition to any other remedy to which such party is entitled at law or in equity. 
 (c) EACH PARTY TO THIS
AGREEMENT WAIVES TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY ANY OF THEM AGAINST THE OTHER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT, OR ANY OTHER AGREEMENTS EXECUTED AND DELIVERED PURSUANT TO OR IN CONNECTION
HEREWITH OR THE NEGOTIATION, BREACH, VALIDITY, TERMINATION OR 

  
 20 

 
PERFORMANCE HEREOF AND THEREOF OR THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY. FURTHER, (I) NO PARTY TO THIS AGREEMENT SHALL SEEK A JURY TRIAL IN ANY SUCH ACTION AND (II) NO PARTY
WILL SEEK TO CONSOLIDATE ANY SUCH ACTION IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE OR HAS NOT BEEN WAIVED. EACH PARTY TO THIS AGREEMENT CERTIFIES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
OR INSTRUMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS SET FORTH ABOVE IN THIS SECTION 4.12. NO PARTY HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY THAT THE PROVISIONS OF THIS SECTION WILL NOT BE FULLY ENFORCED IN
ALL INSTANCES. 
 4.13 Further Assurances; Company Logo. At any time or from time to time after the Effective Date, the parties hereto
agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as any other party may reasonably request in order to evidence or effectuate
the provisions of this Agreement and to otherwise carry out the intent of the parties hereunder. The Company hereby grants the Carlyle Shareholders and their respective Affiliates permission to use the Company’s and its subsidiaries’ name
and logo in marketing materials. 
 4.14 Regulatory Matters. The Company shall and shall cause its subsidiaries to keep the Carlyle
Shareholders informed, on a current basis, of any events, discussions, notices or changes with respect to any criminal or regulatory investigation or action involving the Company or any of its subsidiaries, so that the Carlyle Shareholders and their
respective Affiliates will have the opportunity to take appropriate steps to avoid or mitigate any regulatory consequences to them that might arise from such investigation or action. 

4.15 Inconsistent Agreements. Neither the Company nor any Shareholder shall enter into any agreement or side letter with, or grant any
proxy to, any Shareholder, the Company or any other Person (whether or not such proxy, agreements or side letters are with other Shareholders, holders of Ordinary Shares that are not parties to this Agreement or otherwise) that conflicts with the
provisions of this Agreement or which would obligate such Person to breach any provision of this Agreement. 
 4.16 In-Kind Distributions. If any of the Carlyle Shareholders (and/or any of their Affiliates) seeks to effectuate an in-kind distribution of all or part of its Shares to its
respective direct or indirect equity holders, the Company will, subject to any applicable lock-ups, work with the foregoing Persons to facilitate such in-kind
distribution in the manner reasonably requested and consistent with the Company’s obligations under the Securities Act.  
 4.17
Recapitalization Transactions. If at any time or from time to time there is any change in the capital structure of the Company by way of share split, share dividend, combination or reclassification, or through a merger, consolidation,
reorganization or recapitalization, or by other means, appropriate adjustments will be made in the provision hereof so that the rights and privileges granted hereby will continue.  

[SIGNATURE PAGE FOLLOWS] 

  
 21 

 IN WITNESS WHEREOF, the parties are signing this Principal Shareholders Agreement as of the
date first set forth above. 
  

			
	COMPANY:
	
	        ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
		
	            By:	 	  

		 	Name:
		 	Title:

 
	
	INITIAL CARLYLE SHAREHOLDER:
	
	CARLYLE PARTNERS VI CAYMAN HOLDINGS, L.P.
	
	By: TC Group VI Cayman, L.P.
	Its: General Partner
	
	By: TC Group VI Cayman, L.L.C.
	Its: General Partner
	
	By:                                     
                                         
  
	Name:
	Title: Authorized Person

 EXHIBIT A 

Joinder Agreement 
 By execution of this
signature page, [_______________] hereby agrees to become a Party to, and to be bound by the obligations of, and receive the benefits of, that certain Principal Shareholders Agreement, dated as of
[ 🌑 ], 2021, by and among Ortho Clinical Diagnostics Holdings plc, a public limited company incorporated and registered in England and Wales, and Carlyle Partners VI Cayman Holdings, L.P., a
Cayman Islands exempted limited partnership, and certain other Parties named therein, as amended from time to time thereafter. 
  

	
	[NAME]
	
	By:                                     
                                         
          
	Name:
	Title:
	
	Notice Address:
	
	  

	
	  

  

	
	Accepted:
	
	ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
	
	By:                                     
                                         
  
	Name:
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]